Lawrence Kingsley Sells 2,203 Shares of IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Lawrence Kingsley sold 2,203 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director directly owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $506.53 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The business has a 50 day simple moving average of $556.66 and a 200-day simple moving average of $566.88. IDEXX Laboratories, Inc. has a 12 month low of $504.77 and a 12 month high of $769.98. The stock has a market capitalization of $39.90 billion, a PE ratio of 35.62, a price-to-earnings-growth ratio of 2.75 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the firm posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on IDXX shares. UBS Group boosted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Citigroup lifted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Finally, Barclays cut their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $747.00.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in IDXX. Empowered Funds LLC increased its holdings in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $265,000. Jump Financial LLC boosted its stake in shares of IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after acquiring an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $164,000. Finally, Sei Investments Co. grew its holdings in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.